Pyxis Oncology (PYXS) Shares Outstanding (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Shares Outstanding (Entity) of $62.7 million for Q4 2025, up 4.54% year-over-year from $60.0 million in Q4 2024, and up 0.87% quarter-over-quarter from $62.1 million in Q3 2025.
Pyxis Oncology (PYXS) Shares Outstanding (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Shares Outstanding (Entity) for 6 consecutive years, with $62.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 4.54% year-over-year to $62.7 million; the TTM figure through Dec 2025 stood at $62.7 million (up 4.54% YoY), while the FY2025 annual figure was $62.7 million, up 4.54% from the prior year.
- Shares Outstanding (Entity) improved to $62.7 million in Q4 2025 per PYXS's latest filing, from $62.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $62.7 million in Q4 2025 and bottomed at $1.4 million in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $39.8 million across 5 years, with a median of $41.8 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 2192.15% — and 2025, when it advanced 4.54%.
- Pyxis Oncology's Shares Outstanding (Entity) stood at $8.5 million in 2021, then soared by 311.6% to $35.0 million in 2022, then advanced by 28.02% to $44.8 million in 2023, then surged by 33.99% to $60.0 million in 2024, then grew by 4.54% to $62.7 million in 2025.
- Business Quant data shows PYXS's Shares Outstanding (Entity) at $62.7 million in Q4 2025, $62.1 million in Q3 2025, and $62.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | 63.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.14 Mn |
| Dec 31, 2025 | 62.14 Mn |
| Sep 30, 2025 | 62.56 Mn |
| Jun 30, 2025 | 61.92 Mn |
| Mar 31, 2025 | 61.05 Mn |
| Dec 31, 2024 | 58.45 Mn |
| Sep 30, 2024 | 60.72 Mn |
| Jun 30, 2024 | 60.50 Mn |
| Mar 31, 2024 | 51.29 Mn |
| Dec 31, 2023 | 39.90 Mn |
| Sep 30, 2023 | 41.33 Mn |
| Jun 30, 2023 | 38.39 Mn |
| Mar 31, 2023 | 35.35 Mn |
| Dec 31, 2022 | 33.03 Mn |
| Sep 30, 2022 | 32.56 Mn |
| Jun 30, 2022 | 32.45 Mn |
| Mar 31, 2022 | 32.32 Mn |
| Dec 31, 2021 | 8.49 Mn |
| Sep 30, 2021 | 1.58 Mn |
| Jun 30, 2021 | 1.47 Mn |